Skip to Content

Posts tagged with "The Dark Side"

  • Biological News

    Visfatin: Real Or Not?

    A commentor to my Proteomics 101 post the other day brought up an important point: that before you can have a chance to figure out what a protein is doing, you have to know that it exists. Finding the darn things is no small job, since you’re digging through piles of chemically similar stuff to… Read More
  • Clinical Trials

    Pecunia Non Olet?

    Today’s New York Times had a long front-page story from Janet Roberts and the paper’s Scourge of the Drug Industry, Gardiner Harris. Titled “After Sanctions, Doctors Get Drug Company Pay”, it details (through the example of one particular Minnesota psychiatrist) a practice of physicians who have had medical board problems co… Read More
  • Clinical Trials

    FDA Advisory Panels: Pay, No Play

    Jim Hu has a good post on some proposed new FDA rules for its advisory panel members. Some sort of changes have been coming for a while now – here’s an op-ed that I wrote on the subject back in 2005. I argued that many of the best scientists and clinicians in a given field… Read More
  • Business and Markets

    The Great Plavix Disaster

    I’ve been remiss in not covering the Plavix situation, which is quite a story. The huge-selling anticoagulant is marketed in the US by Bristol-Meyers Squibb and in the rest of the world by Sanofi-Aventis. It’s been the target of the Canadian generic firm Apotex, who’ve maintained that key parts of its patent coverage are invalid. Read More
  • Cardiovascular Disease

    The New England Journal And Its PR Flacks

    The Wall Street Journal ran an interesting article by David Armstrong the other day on the New England Journal of Medicine and the Merck/Vioxx affair. It’s subscriber-only on the WSJ site, but the Pittsburgh Post-Gazette picked it up here. It brings up an angle that I hadn’t completely considered: While Merck has taken the brunt… Read More
  • Drug Industry History

    Serono’s Suitors

    If you stopped one hundred people on the street and asked them to name a drug company, I’d be astonished if a single one of them mentioned Serono. But they’re one of the largest biotechs in the world, even though their profile is low. Being a privately held (indeed, family-owned) concern surely has something to… Read More
  • Clinical Trials

    This Had Better Be Good

    I wrote a brief wrap-up on the FDA’s concerns about the new Bristol-Meyers Squibb / Merck diabetes drug Pargluva (muraglitazar). It’s officially “approvable”, but the FDA wants more cardiovascular safety data before it can be sold. But just this morning the JAMA web site has rushed out an article from a team at the Cleveland… Read More
  • The Dark Side

    Ghostly Influences

    Via Matthew Herper at Forbes, here’s a real grit-your-teeth article on the ghostwriting of journal articles from inside my industry. Now, I know that this stuff has been going on for a long time in the medical world, and I know that it happens constantly with newspaper op-ed pieces. It’s a growing trend/problem in the… Read More
  • Drug Prices

    So What’s Wrong With A Little Money Changing Hands?

    The marketing practices mentioned in the last posting sound a lot like radio-station payola – paying to get a song on the air. There was an interesting defense of this practice mounted recently over at Marginal Revolution (see the first three postings here. Is there a difference in this case? (I mean, short of the… Read More
  • The Dark Side

    No Defense

    In case anyone has me pegged as a reliable apologist for the pharmaceutical industry, I’d like to direct you to this article in the Sunday New York Times. It details marketing practices (in this case, from Schering-Plough) that, if reported accurately, amount to little more than programmatic bribery of physicians. I can’t defend this st… Read More
...232425